Skip to main content
Loading
  1. Plymouth
    Finding new therapies for brain diseases requires preclinical models and assays with increased clinical relevance. a:head aims to develop a human-based platform for generating complex brain-like tissu ...
  2. Uris
    Actithera is an early-stage radiotherapeutics company with a platform for the design of Theranostics with prolonged tumor retention and rapid peripheral clearance. Its approaches have been validated i ...
  3. Royale
    Antibodies have become the top-selling class of therapeutics stemming from their high level of specificity and affinity for disease proteins as well as their ability to target diverse molecules with a ...
  4. Royale
    Aileron is developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions. With its acquisition of Lung Therapeutics, Aileron is shifting its di ...
  5. Uris
    AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. We take a unique pan-antigenic approach for our cancer v ...
  6. Plymouth
    Reversing osteoarthritis. Introducing an unprecedented category innovation in nanotechnology to fully restore the joint function in osteoarthritic patients, with impeccable results paving the way to c ...
  7. Uris
    Alligator Bioscience is a clinical-stage biotech company developing agonistic antibody-based pharmaceuticals for tumour-directed immunotherapy of cancer. Our lead asset, mitazalimab, a second generati ...
  8. Royale
    Allyx Therapeutics was founded in 2019 by a group of seasoned biopharma industry executives, venture capitalists, and scientific experts. The company aims to deliver a novel approach to preserve and p ...
  9. Plymouth
    Alphyn is developing first-in-class Multi-Target Therapeutics® for severe and prevalent skin diseases based on its AB-101 platform, which has multiple bioactive compounds and, therefore, multiple mech ...
  10. Uris
    Apricity Health is a precision oncology company at the intersection of digital health, AI and biotechnology. It pioneers Dynamic Precision™, which mines longitudinal clinical and molecular data from p ...
  11. Plymouth
    Ashvattha is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precisely targets r ...
  12. Uris
    At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond to exist ...
  13. Plymouth
    AyuVis is pioneering novel small molecule immunotherapies to prevent/treat inflammatory and infectious diseases based on a platform technology of macrophage modulation for a balanced immune response. ...
  14. Uris
    Bexion Pharmaceuticals is a mid-clinical stage biotechnology company developing biologics for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). Our lead asset ...
  15. Uris
    Biograil is developing the proprietary technology BIONDD(TM) capsule delivering biologic drugs with a bioavailability like SC injection creating a broad platform for oral delivery of drugs that would ...
  16. Royale
    BioHarvest Sciences has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial plant-based compounds, at an industrial scale, without the need to gro ...
  17. Uris
    BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with curre ...
  18. Plymouth
    Bionomics, a publicly listed clinical late-stage company focused on addressing unmet needs in CNS. We are developing BNC-210, a Ph3-Ready First- and-Best-in-Class α-7 Nicotinic Receptor for the Treatm ...
  19. Plymouth
    BRINTER, a first-mover US medical technology firm with 3D bioprinted universal human cartilage platform (BioMods™) for the $10B+ cartilage repair market. Our first 510(k) Nose-BioMod™ product is estim ...
  20. Plymouth
    Caledon Biosciences is a privately held, start-up founded in October 2023. Caledon owns the key assets, management and operations of a former NASDAQ listed entity, Liminal BioSciences Inc, which was r ...
  21. Plymouth
    Calissa Therapeutics is a clinical stage dermatology company targeting vascular lesions. Our lead indications are rosacea and port wine birthmark, one of the most common birthmarks. Lead asset CX-001 ...
  22. Uris
    Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to hel ...
  23. Uris
    Carina Biotech is a clinical stage immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CN ...
  24. Plymouth
    A Clinical-stage Biotech Company Developing ‘Off-the-shelf’ Non-gene Modified Hematopoietic Stem Cells & Its Derived Immune Cell Therapies For Cancer Patients.
  25. Royale
    CervoMed is a clinical stage company targeting synaptic dysfunction to treat age-related neurologic disorders. The Company is currently developing neflamapimod, an oral small molecule brain penetrant ...
  26. Uris
    Chimeric Therapeutics, is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric is developing two first in class autolog ...
  27. Uris
    Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunc ...
  28. Plymouth
    Coastar Therapeutics is a venture-backed biotech company based in San Diego, CA, focused on next generation gene delivery technology. The company has developed a novel ENHEnS application that can coat ...
  29. Royale
    Cognigenics is a privately held pre-clinical neuro-engineering company pioneering the frontier of RNA based therapeutics and focused on developing and commercializing innovative genetic medicines to t ...
  30. Uris
    Concerto Biosciences creates breakthrough microbe-based products originating from our unmatched understanding of microbial ecology. Microbes in, on, and around us work in concert to improve human heal ...
  31. Uris
    Cyclacel is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. The transcriptional regu ...
  32. Uris
    CyGenica, a pioneering biotech startup, revolutionises intracellular therapeutics development through their drug delivery platform, GEENIE, which promises to redefine the landscape of pharmaceutical t ...
  33. Uris
    Cytovation is a clinical-stage oncology biotech focused on the development of CyPep-1, a first-in-class synthetic peptide designed to drive a systemic anti-cancer immune response, with a unique dual m ...
  34. Uris
    Clinical Efficacy in the Toughest Cancers -- Cracking the Code on Dendritic Cell Therapy and Tumor Infiltrating Lymphocytes Diakonos Oncology is developing two cell therapy technologies developed at M ...
  35. Royale
    Diamyd Medical is a Stockholm-based, precision medicine company developing an antigen-specific immunotherapy for the treatment and prevention of (autoimmune) Type 1 Diabetes in a genetically defined r ...
  36. Plymouth
    Editpep produces CRISPR based therapeutics by leveraging the Transporter peptide based delivery platform, focusing on CNS and eye indications.
  37. Plymouth
    EG 427 develops a unique vector platform to deliver pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in s ...
  38. Plymouth
    Elsie Bio is focused on applying medicinal chemistry to oligonucleotide development. We use DNA encoded technology to design and develop optimal RNA therapeutics. Our approach is redefining how we tre ...
  39. Plymouth
    EosDx is creating a new modality for AI-driven cancer detection using Bio-crystallography that identifies cancer biomarkers in tissue using a non-invasive, safe, accurate, and objective test
  40. Plymouth
    Epion Therapeutics is developing a minimally invasive treatment for keratoconus that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-link ...
  41. Plymouth
    Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medic ...
  42. Royale
    EVast Bio is a US-based, clinical-stage biotech born as a result of ground-breaking work at C4C (https://c4c.cl). EVast Bio is devoted to exploring the vast potential of small Extracellular Vesicles ( ...
  43. Plymouth
    First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently adva ...
  44. Plymouth
    Garuda’s mission is to bring curative blood stem cell therapy to patients worldwide suffering from serious diseases, while eliminating the dependency on donor or patient cells for transplants. Garuda’ ...
  45. Plymouth
    GenEndeavor is a molecular diagnostics technology company on a mission to prevent genetic and infectious diseases by quickly and accurately detecting pathological biomarkers in early stages.
  46. Uris
    Celebrating its 20th anniversary, Genesis Healthcare is Japan’s leading genetic testing and research company, servicing medical institutions, government, corporations, and individuals to benefit from ...
  47. Plymouth
    Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fi ...
  48. Royale
    Gentas' mission is to bridge BioPharma’s translational gap by providing preclinical testing services using miniature swine models. Gentas will dramatically improve the success rate for testing by 1) i ...
  49. Royale
    GeoVax is developing novel therapies and vaccines for solid tumor cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedept ...
  50. Plymouth
    Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by adv ...
  51. Royale
    Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Humanetics entered the field of radiation modulators through a cooperative research ...
  52. Uris
    ImmuneOnco is a HongKong stock exchange-listed, clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer. The most advanced clinical program is timdarpacept ...
  53. Plymouth
    Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune deficits. Immunis has developed a novel method to grow human cells for clinical us ...
  54. Royale
    IN8bio, a clinical-stage biopharmaceutical company, focuses on gamma-delta T cell product candidates for solid and liquid tumors. These T cells, naturally differentiating between healthy and diseased ...
  55. Uris
    Indaptus Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy ...
  56. Royale
    Inimmune is a private clinical stage company dedicated to developing immuno-therapeutics. It is focused on advancing its Toll Like Receptor ligand portfolio as immunotherapeutics and vaccine adjuvants ...
  57. Uris
    Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein, secreted frizzled related protein 2 (SFFRP2), that ...
  58. Uris
    Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill t ...
  59. Uris
    At Intrepid Labs, we're pioneering the future of drug development through advanced AI, robotics, and drug formulation science. Our mission is to enhance patient care by making treatments more personal ...
  60. Plymouth
    IVIEW Therapeutics Inc. is a clinical-stage ophthalmology-focused therapeutics company based in Cranbury, New Jersey committed to the treatment of ocular diseases with high unmet medical needs through ...
  61. Plymouth
    Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals ...
  62. Plymouth
    Jan Biotech, Inc. has developed a disruptive RNA detection technology that provides unprecedented prediction accuracy (0.97) for time to rebound for antiretroviral treated HIV-infected individuals and ...
  63. Plymouth
    Kanglin Biotechnology (Hangzhou) Co., Ltd. was founded in 2015 with the goal of translating advances in genetic science into curative treatments for previously incurable diseases. We believe in the gr ...
  64. Uris
    Kernal Bio is a biotech company developing mRNA 2.0 immunotherapies. Kernal mines translatome data to discover cell-specific sequence features and design mRNAs that are selectively translated in cance ...
  65. Uris
    Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate imm ...
  66. Uris
    Larkspur Biosciences is pioneering a new wave of cancer therapy by developing medicines that target immune evasion where it starts – in the cancer. Our integrated discovery and translational approach ...
  67. Uris
    Leapfrog Bio is a seed stage company focused on developing precision therapeutics targeting solid tumors caused by loss of function mutations. Since inception in 2019 the company has developed and val ...
  68. Uris
    Likarda has pioneered a groundbreaking platform for hydrogel delivery systems, offering both long- and short-term solutions that can either provide complete immuno-protection or degrade gradually. Thi ...
  69. Uris
    Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and othe ...
  70. Uris
    Luminary stands out as a clinical stage CAR-T therapy company utilizing a unique allogeneic manufacturing platform. Our CAR and TCR development revolve around gamma delta cells, giving our allogeneic ...
  71. Royale
    Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra’s LYNX® drug delivery platform is one of the most significant advances in oral drug deli ...
  72. Plymouth
    Mercy BioAnalytics is a pre-commercial diagnostics company on a mission to save lives and relieve suffering through the early detection of cancer. We are developing ,broadly accessible, inexpensive, b ...
  73. Uris
    MERLIN Biotech is a pre-clinical stage mRNA platform company with a novel 1st in class cancer immunotherapy with exclusive IP in major worldwide markets. Our target, USP6, has demonstrated invivo effi ...
  74. Plymouth
    Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.
  75. Plymouth
    Navega Therapeutics' mission is to develop durable relief for chronic and complex diseases, via DNA gene regulation. The company’s technology is centered around a ZF-AI, a proprietary deep learning al ...
  76. Plymouth
    Neurocentrx is seeking the 1st FDA approval of an abuse-deterrent oral ketamine therapy for depression suitable for clinical and home administration. The company is Phase 3 ready, with a patent abuse- ...
  77. Plymouth
    A new brain liquid biopsy - Neuron Derived Exosomes, their use, and their promise in disease stratification.
  78. Plymouth
    Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is head ...
  79. Uris
    Nobias Therapeutics is a biotechnology company pioneering deep phenotyping to discover advanced therapeutics. Nobias uses its cutting-edge, applied AI platform to distill disease drivers and optimal p ...
  80. Royale
    NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipola ...
  81. Plymouth
    Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the gl ...
  82. Plymouth
    Ocuphire Pharma is a late clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders.
  83. Uris
    Oncoteq is a clinical stage oncology biotech with a focus on first or best-in-class treatments in areas of high unmet need. The company portfolio comprises two highly differentiated assets. TEQ103 has ...
  84. Plymouth
    ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed ...
  85. Uris
    Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (known as GP-2250). Panavance was formed in 2021 as a carve out ...
  86. Plymouth
    Papillon Therapeutics is advancing gene therapy treatments for life threatening conditions with neurologic disease, including Friedreich's ataxia, Danon disease, and Alzheimer’s disease. We specialize ...
  87. Uris
    Portal Instruments is a clinical-stage drug delivery and digital health company transforming injectable biologics into 21st century therapies that are needle-free and seamlessly cloud-connected. Porta ...
  88. Uris
    Predictive Oncology is a science-driven company leveraging its proprietary artificial intelligence (AI) and machine learning capabilities, a proprietary, extensive biorepository of tumor samples, Clin ...
  89. Uris
    Processa Pharmaceuticals is a clinical stage pharmaceutical company developing Next Generation Chemotherapies (NGCs) to address the underlying challenges of current drugs by modifying pharmacokinetics ...
  90. Plymouth
    ProMIS Neurosciences (Nasdaq:PMN) is a Cambridge, Massachusetts and Toronto, Ontario-based clinical stage biotechnology company committed to the discovery and development of therapeutic antibodies sel ...
  91. Plymouth
    Protalix is a commercial-stage biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based express ...
  92. Plymouth
    PTM Therapeutics is a pre-clinical stage antibody therapeutics company developing therapies through targeting post-translational modifications for the treatment of inflammatory bowel disease and solid ...
  93. Uris
    Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been sh ...
  94. Uris
    Reglagene is revolutionizing brain disease therapy by targeting tubulin with a groundbreaking class of selective inhibitors. Our novel compounds, led by RGN6024, offer a blend of oral administration, ...
  95. Uris
    tbc
  96. Plymouth
    Rejuvenation Technologies in developing therapeutics to extend telomeres to combat diseases of aging.
  97. Plymouth
    Pioneering marcrophage cell therapy to transform the outcomes of patients with End Stage Liver Disease
  98. Royale
    Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revela ...
  99. Royale
    Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, ...
  100. Royale
    At this meeting, we will present "Losing Fat Mass without Impacting Muscle Mass: A New Approach for Weight Loss". Ridgeline is developing transformative oral drugs for the multi-billion obesity and mu ...
  101. Royale
    SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully-human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalesc ...
  102. Plymouth
    Saghmos Therapeutics is developing ST-62516 to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary ...
  103. Uris
    Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that driv ...
  104. Uris
    Satellite Bio is a well-funded regenerative medicine company with cutting-edge hepatocyte technologies designed to tackle a broad range of liver diseases. Our platform encompasses a proprietary primar ...
  105. Royale
    Scenic Biotech is at the forefront of identifying genetic modifiers, naturally occruing genes that compensate for mutations resposnible for severe diseases. Leveraging our proprietary Cell-seq platfor ...
  106. Uris
    SciTech is a clinical-stage oncology-focused drug delivery technology company. Our initial clinical trial is underway with IRB-approved sites at UPMC, Columbia University, MD Anderson, USC, U Michigan ...
  107. Plymouth
    Seek Labs is developing next generation molecular diagnostics technologies that have the potential to revolutionize the detection and treatment of diseases. Point of care diagnostics is currently limi ...
  108. Uris
    SeraGene Therapeutics is a pre-clinical stage company using RNA and nanomedicine technology to provide long lasting, targeted control for coagulation disorders. Leveraging a deep understanding of clot ...
  109. Plymouth
    Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. The Co ...
  110. Plymouth
    SIRPant Immunotherapeutics, Inc., a clinical stage company, programs the cells that drive immunity – macrophages – to mobilize effective polyclonal anti-cancer immune responses, providing a novel mult ...
  111. Uris
    Starton is a clinical-stage biotechnology company transforming standard of care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to liv ...
  112. Royale
    Supernova Bio is a R&D-focused bio-venture that has developed therapeutic agents for lipolysis, anti-lipoma, and liposarcoma by utilizing gas-generating polymer nanoparticles that significantly reduce ...
  113. Plymouth
    Sustained Therapeutics is a clinical stage company utilizing advanced clinical and research expertise to develop a patented novel locally injected sustained-release drug delivery platform. This platfo ...
  114. Uris
    Tactical Therapeutics, Inc is a clinical stage private Co in New York, developing Carboxyamidotriazole orotate (CTO) which has shown safety and efficacy in primary brain cancer and many undruggable he ...
  115. Royale
    Tonix is a biopharmaceutical company commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is fo ...
  116. Royale
    Uvax Bio is a clinical stage, privately funded biotechnology company focused on developing vaccines to address unmet clinical needs in the prevention of infectious diseases. Uvax Bio holds the exclusi ...
  117. Royale
    Vasomune Therapeutics Inc., is a clinical stage biopharma, with an asset in mid-phase 2a. AV-001, is a Tie-2 agonist that corrects vascular endothelial dysfunction and shows strong activity against li ...
  118. Uris
    VerImmune Inc is developing a highly innovative Virus-inspired Particle (ViP™) platform technology that has the potential to treat multiple diseases, with an initial focus on Oncology.
  119. Uris
    Vincogen corporation (www.vincogen.com) is the Biotechnology - Artificial Intelligence company and has developed VincoAI, a collection of generative AI models. VincoAI is the first proof-of-concept ge ...
  120. Royale
    Ziphius is a biotechnology company focused on the development of self-amplifying RNA-based (saRNA) vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to all ...
  121. Uris
    ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology. [ ...
  122. Royale
    ZWI Therapeutics is a US biotechnology company developing novel protein therapeutics linked to a novel polymer. The company’s new proprietary polymer shows improved pharmacokinetics and reduced potent ...
  123. Royale
    ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory disea ...
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP